Screening of drug candidates for their drug- drug interaction potential

Current Opinion in Chemical Biology

Volumn 5, Issue 4, 2001, Pages 396-401

  Rodrigues, A David ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P;

ANALYTIC METHOD; CALCULATION; CORRELATION FUNCTION; DATA BASE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 0035415865     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00220-9     Document Type: Review

References (50)

1. Inhibition and induction of cytochrome P450 and the clinical implications
2. The potential pharmacological and toxicological impact of P450 screening
3. In vitro models for early studies of drug metabolism
4. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery
5. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes
6. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
7. In vitro assessment of human cytochrome P450
8. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry
9. Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates
10. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites
11. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates
12. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s
13. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes
14. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe
15. Development of a non-HPLC assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes
16. 14C]phenacetin O-deethylase activity in human liver microsomes
17. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential
18. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6)
19. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: Towards the prediction of human P450 substrate specificity and metabolism
20. Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries
21. A novel approach to predicting P450 mediated drug metabolism: CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6
22. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors
23. A refined 3-dimensional QSAR of cytochrome P450 2C9: Computational predictions of drug interactions
24. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors
25. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of cytochrome P450 3A4 inhibitors
26. Effect of omeprazole on diazepam disposition in the rat: In vitro and in vivo studies
27. i values and impact of CYP3A5 expression
28. A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4
29. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
30. In vitro prediction the terfenadine-ketoconazole pharmacokinetic interaction
31. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine and by azole antifungal agents
32. Induction of human drug-metabolizing enzymes: Pharmacological and toxicological implications
33. Inhibition and induction of human cytochrome P450 (CYP) enzymes
34. Regulation of cytochrome P450 (CYP) genes by nuclear receptors
35. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions
36. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene
37. Enzyme induction in the cytochrome P450 system
38. Role of pharmacokinetics and metabolism in drug discovery and development
39. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin
40. Refinement of an in vitro cell model for cytochrome P450 induction
41. Effect of cryo-preservation on cytochrome P450 enzyme induction in cultured rat hepatocytes
42. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: Consensus of an international expert panel
43. Induction of cytochrome P450 in cryopreserved rat and human hepatocytes
44. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction
45. Quantitative RT-PCR measurement of human cytochrome P-450s: Application to drug induction studies
46. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: Role of the glucocorticoid and pregnane X receptors
47. Use of the nuclear receptor PXR to predict drug interactions
48. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro
49. Humanized xenobiotic response in mice expressing nuclear receptor SXR